BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Why Is BeiGene Stock Trading Higher On Wednesday?
European Commission Approves Products by BeiGene, GSK and Novartis
Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks
BeiGene Has Entered Into A Settlement Agreement With MSN Pharmaceuticals And MSN Laboratories Private Resolving Patent Litigation Related To MSN's Abbreviated New Drug Application Seeking Approval To Market A Generic Version Of Brukinsa (Zanubrutinib)...
Cui Nyonya Kueh :